RxDoctor Payments Data

Daniel Fronk, MD

Cardiovascular Disease · Farmington, UTNPI 1639515869

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $8,533 of the $12,754 with a category attached, or 66.9%. Medtronic accounts for 63.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $8,642 and has fallen 76.0% since, to $2,074 in 2025.

$12,754in general payments, 2019–2025

Across 94 payments — averaging $135.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Endologix LLC$2K
  • Abbott$1K
  • Edwards Lifesciences$649
  • Boston Scientific$405
  • Inari Medical, Inc.$212
  • plus $568 from 15 others

What the payments were for

  • Travel & lodging$8,53367%
  • Food & beverage$4,22133%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,754 in reported general payments places this provider in the 80th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$456,850
Medicare patients
792
Services billed
3,491

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$135,501
XareltoRivaroxaban96$120,586
BrilintaTicagrelor52$37,465
FarxigaDapagliflozin Propanediol20$30,260
Repatha SureclickEvolocumab29$17,381
EntrestoSacubitril/Valsartan11$16,554
Bumetanide24$2,098
Rosuvastatin Calcium163$1,993
Metoprolol Succinate123$1,958
Ranolazine ErRanolazine25$1,709
Amiodarone Hcl108$1,611
Prasugrel Hcl21$1,400
Atorvastatin Calcium146$1,320
ClopidogrelClopidogrel Bisulfate134$1,239
Losartan Potassium120$1,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$103$16,55411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Farmington

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →